OrbiMed Advisors VTGN Position
Active3-Fund ConvergenceOrbiMed Advisors held their position in Vistagen Therapeutics, Inc. (VTGN) in Q4 2025, holding $2.0M worth of shares across 3,060,000 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
VTGN is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Fasedienol Nasal Spray - Placebo Nasal Spray in 14 days (Apr 30, 2026), making the timing of OrbiMed's position particularly relevant.
About Vistagen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
4.7%
1.7 days to cover
OrbiMed Advisors VTGN Position History
Frequently Asked Questions
Does OrbiMed Advisors own VTGN?
Yes. As of Q4 2025, OrbiMed Advisors holds 3,060,000 shares of Vistagen Therapeutics, Inc. (VTGN) valued at $2.0M. This data comes from their SEC 13F filing.
How many hedge funds own VTGN?
3 specialist biotech hedge funds currently hold VTGN, including BVF Partners, Commodore Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy VTGN?
OrbiMed Advisors's position in VTGN was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's VTGN position increasing or decreasing?
OrbiMed Advisors held their VTGN position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VTGNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →